Reference : Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/20293
Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years.
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique >]
Sawicki, A. [> > > >]
Roces-Varela, A. [> > > >]
Fardellone, Patrice [> > > >]
Roberts, A. [> > > >]
Devogelaer, Jean-Pierre [> > > >]
2009
BONE
45
1059-64
Yes (verified by ORBi)
International
8756-3282
1873-2763
[en] BMD Fracture risk ; Long-term treatment ; Safety ; Strontium ranelate
[en] OBJECTIVES: Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This article describes the efficacy, safety, and tolerability of this agent over 8 years. METHODS: Postmenopausal osteoporotic women having participated in the 5-year efficacy trials SOTI and TROPOS were invited to enter a 3-year open-label extension study. The results presented here focus on patients who received strontium ranelate for 8 years. RESULTS: At the extension baseline, the population treated for 8 years (n=879; 79.1+/-5.6 years) had femoral neck T-score of -2.61+/-0.71. The cumulative incidences of new vertebral and nonvertebral fractures (13.7% and 12.0%, respectively) over years 6 to 8 were non-statistically different from the cumulative incidences in the first 3 years of the original studies (11.5% and 9.6%). Lumbar spine, femoral neck, and total hip bone mineral density (BMD) increased throughout the 8-year period. Annual relative change in BMD was significant at every visit, except the 8-year visit for femoral neck and total hip BMD. Strontium ranelate was safe and well tolerated over 8 years. CONCLUSIONS: Long-term treatment with strontium ranelate 2 g/day in postmenopausal osteoporotic women leads to continued increases in BMD at all sites. The data also provide some evidence for a sustained antifracture efficacy.
http://hdl.handle.net/2268/20293
10.1016/j.bone.2009.08.004

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Long-term_Tx_PM_osteoporosis_with_strontium_ranelate_Results_at_8years.pdfPublisher postprint417 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.